158 related articles for article (PubMed ID: 36080216)
1.
Cruz-Nova P; Ocampo-García B; Carrión-Estrada DA; Briseño-Diaz P; Ferro-Flores G; Jiménez-Mancilla N; Correa-Basurto J; Bello M; Vega-Loyo L; Thompson-Bonilla MDR; Hernández-Rivas R; Vargas M
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080216
[TBL] [Abstract][Full Text] [Related]
2. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo.
Cruz-Nova P; Schnoor M; Correa-Basurto J; Bello M; Briseño-Diaz P; Rojo-Domínguez A; Ortiz-Mendoza CM; Guerrero-Aguirre J; García-Vázquez FJ; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
BMC Cancer; 2018 Nov; 18(1):1056. PubMed ID: 30382908
[TBL] [Abstract][Full Text] [Related]
3. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
4. Antineoplastic effect of compounds C14 and P8 on TNBC and radioresistant TNBC cells by stabilizing the K-Ras4B
Carrión-Estrada DA; Aguilar-Rojas A; Huerta-Yepez S; Montecillo-Aguado M; Bello M; Rojo-Domínguez A; Arechaga-Ocampo E; Briseño-Díaz P; Meraz-Ríos MA; Thompson-Bonilla MDR; Hernández-Rivas R; Vargas M
Front Oncol; 2024; 14():1341766. PubMed ID: 38571493
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling.
Muratcioglu S; Aydin C; Odabasi E; Ozdemir ES; Firat-Karalar EN; Jang H; Tsai CJ; Nussinov R; Kavakli IH; Gursoy A; Keskin O
J Mol Biol; 2020 Feb; 432(4):1199-1215. PubMed ID: 31931009
[TBL] [Abstract][Full Text] [Related]
7. Dissociation of the Signaling Protein K-Ras4B from Lipid Membranes Induced by a Molecular Tweezer.
Li L; Erwin N; Möbitz S; Niemeyer F; Schrader T; Winter RHA
Chemistry; 2019 Jul; 25(42):9827-9833. PubMed ID: 31141233
[TBL] [Abstract][Full Text] [Related]
8. Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.
Jang H; Banerjee A; Chavan T; Gaponenko V; Nussinov R
J Biol Chem; 2017 Jul; 292(30):12544-12559. PubMed ID: 28623230
[TBL] [Abstract][Full Text] [Related]
9. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
[TBL] [Abstract][Full Text] [Related]
10. The Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function.
Abdelkarim H; Banerjee A; Grudzien P; Leschinsky N; Abushaer M; Gaponenko V
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739603
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
Aran V; Masson Domingues P; Carvalho de Macedo F; Moreira de Sousa CA; Caldas Montella T; de Souza Accioly MT; Ferreira CG
Lung Cancer; 2018 Feb; 116():7-14. PubMed ID: 29413054
[TBL] [Abstract][Full Text] [Related]
12. 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
Nastasă C; Tamaian R; Oniga O; Tiperciuc B
Medicina (Kaunas); 2019 Mar; 55(4):. PubMed ID: 30935124
[No Abstract] [Full Text] [Related]
13. GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site.
Lu S; Banerjee A; Jang H; Zhang J; Gaponenko V; Nussinov R
J Biol Chem; 2015 Nov; 290(48):28887-900. PubMed ID: 26453300
[TBL] [Abstract][Full Text] [Related]
14. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif.
Tsai FD; Lopes MS; Zhou M; Court H; Ponce O; Fiordalisi JJ; Gierut JJ; Cox AD; Haigis KM; Philips MR
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):779-84. PubMed ID: 25561545
[TBL] [Abstract][Full Text] [Related]
15. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region.
Jang H; Abraham SJ; Chavan TS; Hitchinson B; Khavrutskii L; Tarasova NI; Nussinov R; Gaponenko V
J Biol Chem; 2015 Apr; 290(15):9465-77. PubMed ID: 25713064
[TBL] [Abstract][Full Text] [Related]
17. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
[TBL] [Abstract][Full Text] [Related]
18. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.
Lu S; Jang H; Nussinov R; Zhang J
Sci Rep; 2016 Feb; 6():21949. PubMed ID: 26902995
[TBL] [Abstract][Full Text] [Related]
19. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin.
Abraham SJ; Nolet RP; Calvert RJ; Anderson LM; Gaponenko V
Biochemistry; 2009 Aug; 48(32):7575-83. PubMed ID: 19583261
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of K-Ras4B-plasma membrane association with a membrane microdomain-targeting peptide.
Li FY; Zhang ZF; Voss S; Wu YW; Zhao YF; Li YM; Chen YX
Chem Sci; 2019 Dec; 11(3):826-832. PubMed ID: 34123058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
